Chemotherapy-Induced Nausea
FDA-approved THC derivatives with decades of clinical evidence
Chemotherapy-induced nausea and vomiting (CINV) has the longest regulatory history of any cannabinoid indication. Dronabinol and nabilone have been FDA-approved since the 1980s and are used as second-line antiemetics when standard treatments fail.
At a Glance
Overview
Chemotherapy-induced nausea and vomiting (CINV) affects 70–80% of patients receiving chemotherapy and is one of the most feared side effects of cancer treatment. Despite advances in antiemetic therapy (5-HT3 antagonists, NK1 antagonists, corticosteroids), 30–40% of patients still experience breakthrough or refractory CINV.
Dronabinol (synthetic THC) received FDA approval for CINV in 1985, making it one of the earliest approved cannabinoid pharmaceuticals. Nabilone (a synthetic THC analog) was approved in 1985 as well. Both are Schedule II/III controlled substances used as second-line antiemetics.
The antiemetic mechanism of THC involves CB1 receptor activation in the dorsal vagal complex and nucleus tractus solitarius — brainstem regions that regulate the vomiting reflex. THC also acts on the chemoreceptor trigger zone in the area postrema.
A 2015 Cochrane review of 23 RCTs found cannabis-based medicines were more effective than placebo and as effective as conventional antiemetics (prochlorperazine, metoclopramide) for CINV. However, they were associated with more adverse effects (sedation, dizziness, dysphoria) than modern 5-HT3 antagonists.
The clinical role of cannabinoids in CINV has evolved: they are now primarily used as add-on therapy for refractory CINV when first-line agents (ondansetron, aprepitant, dexamethasone) have failed, rather than as first-line treatment.
Symptoms
- Acute nausea (0–24 hours post-chemo)
- Delayed nausea (24–120 hours post-chemo)
- Anticipatory nausea (conditioned response)
- Vomiting
- Anorexia
- Dehydration
- Weight loss
How Cannabis Helps
THC activates CB1 receptors in the brainstem's vomiting control centers (dorsal vagal complex, nucleus tractus solitarius, area postrema), suppressing the emetic reflex. It also reduces anticipatory nausea through central anxiolytic effects.
Treatment Options
Graded by quality of evidence. Grade A = strong (RCTs/FDA approval); B = moderate; C = preliminary.
Dronabinol (synthetic THC)
Oral capsule (Marinol)
FDA-approved for CINV. Multiple RCTs confirm efficacy. Second-line after 5-HT3 antagonists.
5–10 mg 1–3 hours before chemotherapy, then every 2–4 hours after
Nabilone (synthetic THC analog)
Oral capsule (Cesamet)
FDA-approved for CINV. Similar efficacy to dronabinol. May be preferred for refractory cases.
1–2 mg BID; start 1–3 hours before chemotherapy
Inhaled cannabis
Vaporized
Faster onset than oral. Limited RCT data for CINV specifically. Used by patients who cannot tolerate oral medications.
Key Studies
Primary literature supporting the evidence grade for this indication.
Cannabis-based medicines for chemotherapy-induced nausea and vomiting
Grade ACochrane Database of Systematic Reviews, 2015
23 RCTs. Cannabis-based medicines more effective than placebo; comparable to conventional antiemetics.
Cannabinoids for control of chemotherapy induced nausea and vomiting
Grade ABMJ, 2001
Meta-analysis: cannabinoids superior to prochlorperazine and metoclopramide for CINV.
Side Effects to Watch
- Sedation and dizziness
- Dysphoria and anxiety (especially in older patients)
- Tachycardia
- Orthostatic hypotension
- Cognitive impairment
Who Should Avoid
- History of psychosis or schizophrenia
- Severe cardiovascular disease
- Elderly patients (increased sensitivity to psychoactive effects)
- Patients with history of substance use disorder
Dosing Guidance
Dronabinol: 5 mg/m² 1–3 hours before chemotherapy, then every 2–4 hours after (max 4–6 doses/day). Nabilone: 1–2 mg BID, starting 1–3 hours before chemotherapy. Both are prescription-only. Use lowest effective dose to minimize psychoactive side effects.
Dosing information is for educational purposes only. Consult a licensed healthcare provider for personalized guidance.
Clinician Note
Cannabinoids are second-line antiemetics for CINV — use after 5-HT3 antagonists (ondansetron), NK1 antagonists (aprepitant), and corticosteroids have been optimized. Elderly patients are particularly sensitive to psychoactive effects. Consider nabilone over dronabinol for patients with severe refractory CINV.
Related Conditions
Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Cannabis remains a Schedule I controlled substance federally in the U.S. Always consult a qualified healthcare provider before making any medical decisions. Individual responses to cannabinoids vary significantly.